Overview

Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

Status:
Completed

Trial end date:
2020-08-01

Target enrollment:

Participant gender:

Summary

To assess the effect of SGLT-2 inhibitors on blood pressure and urinary angiotensinogen. This is a cross over study design, where 40 subjects will receive Dapagliflozin for 6 weeks followed by placebo for 6 weeks, or placebo for 6 weeks followed by Dapagliflozin for 6 weeks. In addition there will be an arm of 10 subjects who will receive sulfonylurea in an open label as a comparative to the cross over subjects to assess if the effect of Dapagliflozin may also be in part due to improved glycemic control.

Phase:

Phase 4

Details

Lead Sponsor:

Tulane University
Tulane University School of Medicine

Collaborator:

AstraZeneca

Treatments:

Angiotensin II
Angiotensinogen
Dapagliflozin